How the Epidemiology of Hodgkin Lymphoma Changed in Debrecen, Hungary

Main Article Content

László Pinczés Zsófia Miltényi Ádám Jóna Ferenc Magyari Kata Husi Árpád Illés


Introduction. Hodgkin lymphoma shows a well-known geographic pattern. Incidence also varies significantly by age, sex, ethnicity and socioeconomic status. These clinical pathological features of the disease are changing. Patients and methods. 715 Hodgkin lymphoma patients’ clinicopathological and treatment data were assessed in a maximum of ten-year periods. The patients were treated at the University of Debrecen, Department of Hematology from 1980 until the end of 2014. Results. The first period (1980-89) contained 193, the second (1990-99) 199, the third (2000-09) 236 and the fourth (2010-14) 87 Hodgkin lymphoma patients. The mean age of the patients were 39, 34.5, 38 and 36.8 years respectively. The male/female ratio was 1.29, 1.23, 1.03 and 0.97 in order. A unimodal age group pattern can be seen in the first and second periods with an incidence peak between 20 and 29 years of age. Bimodal age group pattern was observed in the third and fourth periods with the first incidence peak between 20 and 29 years of age and the second between 50 and 59 years. The incidence of classical mixed cellularity (cMC) histological subtype is decreasing (38%, 49%, 48% and 26%; p < 0.01) while classical nodular sclerosis (cNS) shows an increasing tendency (21%, 28%, 30% and 50%; p < 0.01). The first peak is predominantly caused by the cNS subtype in the third and fourth period, and the second peak caused by cMC subtype in the third and cNS in the fourth period. The number of advanced stage patients (59%) is beyond the early stage patients (41%) in the last observed period. The 5-year overall survival is increasing (64.2%, 84.6%, 87% and 92%). Discussion. The changing patterns can be explained by the altered nature of the disease, changes in immunological features, environmental factors, socioeconomic status and development of diagnostic and therapy methods.

Article Details

How to Cite
PINCZÉS, László et al. How the Epidemiology of Hodgkin Lymphoma Changed in Debrecen, Hungary. Medical Research Archives, [S.l.], v. 4, n. 6, oct. 2016. ISSN 2375-1924. Available at: <>. Date accessed: 13 apr. 2024.
Hodgkin lymphoma; epidemiology; incidence; age group pattern; overall survival
Review Articles


Bonadonna, G., Bonfante, V., Viviani, S., Di Russo, A., Villani, F., & Valagussa, P. (2004). ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin’s disease: long-term results. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 22(14), 2835–41. doi:10.1200/JCO.2004.12.170

Cancer Research UK. (n.d.). Retrieved from

Carbone, P. P., Kaplan, H. S., Musshoff, K., Smithers, D. W., & Tubiana, M. (1971). Report of the Committee on Hodgkin’s Disease Staging Classification. Cancer Research, 31(11), 1860–1. Retrieved from

Chang, K.-C., Chen, P. C.-H., Jones, D., & Su, I.-J. (2008). Changing patterns in the frequency of Hodgkin lymphoma subtypes and Epstein–Barr virus association in Taiwan. Cancer Science, 99(2), 345–349. doi:10.1111/j.1349-7006.2007.00667.x

Engert, A., Diehl, V., Franklin, J., Lohri, A., Dörken, B., Ludwig, W.-D., … Löffler, M. (2009). Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin’s lymphoma: 10 years of follow-up of the GHSG HD9 study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 27(27), 4548–54. doi:10.1200/JCO.2008.19.8820

European Cancer Observatory - International Agency for Research on Cancer. (n.d.). Retrieved from

Ferlay, J., Steliarova-Foucher, E., Lortet-Tieulent, J., Rosso, S., Coebergh, J. W. W., Comber, H., … al., et. (2013). Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. European Journal of Cancer (Oxford, England : 1990), 49(6), 1374–403. doi:10.1016/j.ejca.2012.12.027

Harris, N. L., Jaffe, E. S., Diebold, J., Flandrin, G., Muller-Hermelink, H. K., Vardiman, J., … Bloomfield, C. D. (1999). World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 17(12), 3835–49. Retrieved from

Hasenclever, D., & Diehl, V. (1998). A prognostic score for advanced Hodgkin’s disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. The New England Journal of Medicine, 339(21), 1506–14. doi:10.1056/NEJM199811193392104

Hjalgrim, H., Smedby, K. E., Rostgaard, K., Molin, D., Hamilton-Dutoit, S., Chang, E. T., … Melbye, M. (2007). Infectious mononucleosis, childhood social environment, and risk of Hodgkin lymphoma. Cancer Research, 67(5), 2382–8. doi:10.1158/0008-5472.CAN-06-3566

Hutchings, M., Loft, A., Hansen, M., Pedersen, L. M., Berthelsen, A. K., Keiding, S., … Specht, L. (2006). Position emission tomography with or without computed tomography in the primary staging of Hodgkin’s lymphoma. Haematologica, 91(4), 482–9. Retrieved from

Illés, Á., Keresztes, K., Miltényi, Z., & Molnár, Z. (2004). A Hodgkin-kór hazai epidemiológiai és kezelési adatai - A Hodgkin-kór Munkacsoport beszámolója. Hematológia - Transzfuziológia, 37(3), 155–165.

Kaye, K. M., Izumi, K. M., & Kieff, E. (1993). Epstein-Barr virus latent membrane protein 1 is essential for B-lymphocyte growth transformation. Proceedings of the National Academy of Sciences of the United States of America, 90(19), 9150–4. Retrieved from

Koch Institute, R., & Centre for Cancer Registry Data, G. (n.d.). German Centre For Cancer Registry Data. Retrieved July 13, 2016, from

Landgren, O., & Caporaso, N. E. (2007). New Aspects in Descriptive, Etiologic, and Molecular Epidemiology of Hodgkin’s Lymphoma. Hematology/Oncology Clinics of North America, 21(5), 825–840. doi:10.1016/j.hoc.2007.07.001

Lister, T. A., Crowther, D., Sutcliffe, S. B., Glatstein, E., Canellos, G. P., Young, R. C., … Tubiana, M. (1989). Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin’s disease: Cotswolds meeting. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 7(11), 1630–6. Retrieved from

Lukes, R. J., Craver, L. F., Hall, T. C., Rappaport, H., & Ruben, P. (1966). Report of the Nomenclature Committee. Cancer Research, 26(6 Part 1), 1311–1311. (n.d.). Retrieved from

Miltényi, Z. (2011). Changing Patterns in the Clinical Pathological Features of Hodgkin Lymphoma: A Report from Debrecen, Hungary Z ofia Miltényi, Z ofia Simon, Edit Páyer, Lászlo Vároczy, Lajos Gergely Adám ona, an Arpád Illés. International Scholarly Research Network ISRN Hematology, 7. doi:10.5402/2011/810708

Salati, M., Cesaretti, M., Macchia, M., Mistiri, M. El, & Federico, M. (2014). Epidemiological Overview of Hodgkin Lymphoma across the Mediterranean Basin. Mediterranean Journal of Hematology and Infectious Diseases, 6(1), e2014048. doi:10.4084/MJHID.2014.048

Swerdlow, S. H., Campo, E., Pileri, S. A., Harris, N. L., Stein, H., Siebert, R., … Jaffe, E. S. (2016). The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood, 127(20), 2375–90. doi:10.1182/blood-2016-01-643569

Tubiana, M., Henry-Amar, M., Carde, P., Burgers, J. M., Hayat, M., Van der Schueren, E., … Thomas, J. (1989). Toward comprehensive management tailored to prognostic factors of patients with clinical stages I and II in Hodgkin’s disease. The EORTC Lymphoma Group controlled clinical trials: 1964-1987. Blood, 73(1), 47–56. Retrieved from

Vardiman, J. W., Thiele, J., Arber, D. A., Brunning, R. D., Borowitz, M. J., Porwit, A., … Bloomfield, C. D. (2009). The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood, 114(5), 937–51. doi:10.1182/blood-2009-03-209262

Weiss, L. M., Movahed, L. A., Warnke, R. A., & Sklar, J. (2010). Detection of Epstein–Barr Viral Genomes in Reed–Sternberg Cells of Hodgkin’s Disease.